Poster SABCS 2018
Department for Obstetrics and Gynecology Hanover Medical School Carl-Neuberg-Str. 1 30625 Hanover, Germany A prospective multicenter real-world study on neoadjuvant treatment and clinical outcome in TNBC patients Kuehnle E1, Kaur P1, Siggelkow W2, Luebbe K2, Schrader I2,7, Noeding S3, Noeding KH4, Noesselt T5, Arfsten M6, Busch C5, Uleer C8, Krentel N1, Hillemanns P1, Dörk T1, Park-Simon TW1 1 Department of Obstetrics and Gynecology, Breast Center, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hanover, Germany 5 Sana Klinikum Hameln-Pyrmont, Breast Center, Saint-Maur-Platz 1, 31785 Hameln, Germany 2 DIAKOVERE Henriettenstift, Breast Center, Schwemannstraßee 17, 30559 Hanover, Germany 6 Kreiskrankenhaus Stadthagen, Breast Center Schaumburg, Am Krankenhaus 1, 31655 Stadthagen, Germany 3 Klinikum Hannover Nordstadt, Cooperative Breast Center Klinikum Region Hanover, Herrenhäuser Kirchweg 5, 30167 Hanover, Germany 7 Gynäkoonkologische Praxis am Pelikan Platz Hannover, Germany 4 HELIOS Klinikum Hildesheim, Breast Center, Senator-Braun-Allee 33, 31135 Hildesheim, Germany 8 Frauenärzte am Bahnhofsplatz, Bahnhofsplatz 5, 31134 Hildesheim, Germany Introduction Results 120.0% Chemotherapy Treatment N (%) Controversy exists with regards to 157/227 patients (69%) received regime dose <80% 100.0% 96.6% Taxan 4 0 0% the optimal regimen for NACT and 70/227 patients (31%) 94.7% neoadjuvant chemotherapy adjuvant chemotherapy. 69/157 Taxan/Platin 14 2 14% 80.0% TAC 28 1 4% 80.0% 75.4% (NACT) of TNBC. Platinum-based (44%) patients achieved pCR EC-Pac/Doc 97 8 8% 66.2% 66.7% regimens seem to be more active (Breast+Axilla). 26/69 (38%) ETC 30 2 7% 60.0% EC-Pac 23 4 17% in TNBC improving pCR rates received platinum-based NACT.
[Show full text]